New gene therapy trial shows promise for heart disease treatment
New gene therapy trial shows promise for heart disease treatment
Updated at: June 3, 2026 at 05:00 AM
A groundbreaking era in cardiovascular medicine is dawning, with recent advances in gene therapy offering new hope for heart disease patients.
Rather than relying on lifelong daily medications, scientists are developing "one-and-done" treatments that target the genetic root of cardiovascular issues.
One major development is VERVE-102, a CRISPR-based therapy designed to disable the PCSK9 gene in the liver.
By doing so, it helps the body clear LDL cholesterol more effectively.
In recent clinical trials, the highest dose of this single-infusion treatment reduced LDL cholesterol by up to 62%, showing potential durability for over a year.
As this technology evolves, the medical community remains focused on integrating these powerful tools ethically, marking a potential shift from managing chronic heart disease to finding lasting cures.
